Patient Decisions about Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 3090-3095

  Ropka, Mary E ^a   Keim, Jess ^a   Philbrick, John T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CHEMOPROPHYLAXIS; DECISION SUPPORT SYSTEM; HUMAN; MEDICAL INFORMATION; META ANALYSIS (TOPIC); PATIENT DECISION MAKING; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ATTITUDE TO HEALTH; BREAST TUMOR; DECISION MAKING; FEMALE; META ANALYSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DECISION MAKING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; META-ANALYSIS AS TOPIC;

EID: 77954573787     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.8077     Document Type: Review

References (49)

1. Jenal A, Siegel R, Ward E, et al: Cancer Statistics, 2009. CA Cancer J Clin 59:1-25, 2009
2. Blaha P, Dubsky P, Fitzal F, et al: Breast cancer chemoprevention: A vision not yet realized. Eur J Cancer Care (Engl) 18:438-446, 2009
3. Nelson H, Fu R, Humphrey L, et al: Comparative effectiveness of medications to reduce risk of primary breast cancer in women. Rockville, MD, Agency for Healthcare Research and Quality, AHRQ Publication No. 09-EHC028-EF, 2009
4. Visvanathan K, Chlebowski RT, Hurley P, et al: American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258, 2009
5. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Breast cancer risk reduction, v. 2.2009. http://www.nccn.org
6. Gail MH: The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann N Y Acad Sci 949:286-291, 2001
7. Freedman AN, Graubard BI, Rao SR, et al: Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95:526-532, 2003 (Pubitemid 36511623)
8. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
9. Kaplan CP, Haas JS, Perez-Stable EJ, et al: Breast cancer risk reduction options: Awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev 15:162-166, 2006
10. Armstrong K, Quistberg DA, Micco E, et al: Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 166:2260-2265, 2006 (Pubitemid 44748773)
11. Mulley AG, Sepucha K: Making good decisions about breast cancer chemoprevention. Ann Intern Med 137:52-54, 2002
12. Lippman SM: The dilemma and promise of cancer chemoprevention. Nature Clinical Practice Oncology 3:523, 2006
13. O'Connor AM, Legare F, Stacey D: Risk communication in practice: The contribution of decision aids. BMJ 327:736-740, 2003 (Pubitemid 37176762)
14. O'Connor AM, Llewellyn-Thomas HA, Flood AB: Modifying unwarranted variations in health care: Shared decision making using patient decision aids. Health Affairs (Millwood) VAR 63-72, 2004 (suppl)
15. Wennberg JE: Unwarranted variations in healthcare delivery: Implications for academic medical centres. BMJ 325:961-964, 2002
16. O'Connor AM, Mulley AG Jr, Wennberg JE: Standard consultations are not enough to ensure decision quality regarding preference-sensitive options. J Natl Cancer Inst 95:570-571, 2003 (Pubitemid 36553496)
17. Briss P, Rimer B, Reilley B, et al: Promoting informed decisions about cancer screening in communities and healthcare systems. Am J Prev Med 26:67-80, 2004 (Pubitemid 38045176)
18. Wang C, Gonzalez R, Merajver SD: Assessment of genetic testing and related counseling services: Current research and future directions. Soc Sci Med 58:1427-1442, 2004 (Pubitemid 38169343)
19. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. Ann Intern Med 151:264-269, 2009
20. Bastian LA, Lipkus IM, Kuchibhatla MN, et al: Women's interest in chemoprevention for breast cancer. Arch Intern Med 161:1639-1644, 2001 (Pubitemid 32681145)
21. Bober SL, Hoke LA, Duda RB, et al: Decision-making about tamoxifen in women at high risk for breast cancer: Clinical and psychological factors. J Clin Oncol 22:4951-4957, 2004 (Pubitemid 46638620)
22. Fasching PA, von Minckwitz G, Fischer T, et al: The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Res Treat 101:95-104, 2007 (Pubitemid 47555333)
23. Fagerlin A, Zikmund-Fisher BJ, Smith DM, et al: Women's decisions regarding tamoxifen for breast cancer prevention: Responses to a tailored decision aid. Breast Cancer Res Treat 119:613-620, 2010
24. Goldenberg VK, Seewaldt VL, Scott V, et al: Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 16:1032-1034, 2007 (Pubitemid 46910109)
25. Julian-Reynier CM, Bouchard LJ, Evans DG, et al: Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: Differences among English, French, and Canadian women. Cancer 92:959-968, 2001 (Pubitemid 32783086)
26. McKay A, Martin W, Latosinsky S: How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide. Breast Cancer Res Treat 94:153-159, 2005
27. Meiser B, Butow P, Price M, et al: Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health (Larchmt) 12:769-778, 2003 (Pubitemid 37361919)
28. Melnikow J, Paterniti D, Azari R, et al: Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 103:1996-2005, 2005
29. Port ER, Montgomery LL, Heerdt AS, et al: Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8:580-585, 2001 (Pubitemid 32735038)
30. Salant T, Ganschow PS, Olopade OI, et al: "Why take it if you don't have anything?" Breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med 21:779-785, 2006 (Pubitemid 43973566)
31. Taylor R, Taguchi K: Tamoxifen for breast cancer chemoprevention: Low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 3:242-247, 2005 (Pubitemid 40806718)
32. Tjia J, Micco E, Armstrong K: Interest in breast cancer chemoprevention among older women. Breast Cancer Res Treat 108:435-453, 2008 (Pubitemid 351431081)
33. Ropka ME, Wenzel J, Phillips EK, et al: Uptake rates for breast cancer genetic testing: A systematic review. Cancer Epidemiol Biomarkers Prev 15:840-855, 2006 (Pubitemid 43823507)
34. Liddle J, Williamson M, Irwig L: Method for evaluating research guideline evidence. Adelaide, Australia, NSW Department of Health, 1996
35. Moher D, Cook DJ, Eastwood S, et al: Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement - QUOROM Group. Br J Surg 87:1448-1454, 2000
36. West S, King V, Carey TS, et al: Systems to rate the strength of scientific evidence. Rockville, MD, Agency for Healthcare Research and Quality, AHRQ Publication No. 02-E016, 2002
37. Stroup DF, Berlin JA, Morton SC, et al: Metaanalysis of observational studies in epidemiology: A proposal for reporting - Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012, 2000
38. NHS Centre for Reviews and Dissemination: Undertaking systematic reviews of research on effectiveness (ed 2). York, United Kingdom, University of York, CRD Report No. 4, 2001
39. Siadaty MS, Philbrick JT, Heim S, et al: Repeated-measures modeling improved comparison of diagnostic tests in meta-analysis of dependent studies. J Clin Epidemiol 57:698-711, 2004 (Pubitemid 39195219)
40. Siadaty M, Shu J: Proportional odds ratio model for comparison of diagnostic tests in metaanalysis. BMC Med Res Methodol 4:27, 2004
41. Chlebowski RT, Collyar DE, Somerfield MR, et al: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol 17:1939-1955, 1999
42. Persky S, Kaphingst KA, Condit CM, et al: Assessing hypothetical scenario methodology in genetic susceptibility testing analog studies: A quantitative review. Genet Med 9:727-738, 2007 (Pubitemid 350129407)
43. Sheeran P: Intention-behavior relations: A conceptual and empirical review. Eur Rev Social Psychol 12:1-36, 2002
44. Cyrus-David MS, Strom SS: Chemoprevention of breast cancer with selective estrogen receptor modulators: Views from broadly diverse focus groups of women with elevated risk for breast cancer. Psycho-Oncology 10:521-533, 2001
45. Heisey R, Pimlott N, Clemons M, et al: Women's views on chemoprevention of breast cancer: Qualitative study. Can Fam Physician 52:624-625, 2006 (Pubitemid 43905427)
46. Paterniti DA, Melnikow J, Nuovo J, et al: "I'm going to die of something anyway": Women's perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis 15:365-372, 2005
47. Waters EA, Weinstein ND, Colditz GA, et al: Aversion to side effects in preventive medical treatment decisions. Br J Health Psychol 12:383-401, 2007 (Pubitemid 47238015)
48. Melnikow J, Birch S, Slee C, et al: Tamoxifen for breast cancer risk reduction: Impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis. Med Care 46:946-953, 2008
49. McKay A, Latosinsky S, Martin W: Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 103:209-210, 2005